You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

~ Buy the TEGSEDI (inotersen sodium) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR TEGSEDI

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for TEGSEDI

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01737398 ↗	Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy	Completed	GlaxoSmithKline	Phase 2/Phase 3	2013-03-15	The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).
NCT01737398 ↗	Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy	Completed	Ionis Pharmaceuticals, Inc.	Phase 2/Phase 3	2013-03-15	The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).
NCT04136184 ↗	NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	Active, not recruiting	Akcea Therapeutics	Phase 3	2020-01-15	To evaluate the efficacy and safety of eplontersen after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398). For more information, please visit http://www.neuro-ttransform.com/.
NCT04136184 ↗	NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	Active, not recruiting	Ionis Pharmaceuticals, Inc.	Phase 3	2020-01-15	To evaluate the efficacy and safety of eplontersen after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398). For more information, please visit http://www.neuro-ttransform.com/.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for TEGSEDI

Condition Name

Chart
Table

Condition Name for TEGSEDI
Intervention	Trials
Amyloidosis	1
Familial Amyloid Polyneuropathy	1
FAP	1
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for TEGSEDI
Intervention	Trials
Polyneuropathies	2
Amyloidosis	2
Amyloid Neuropathies	2
Amyloid Neuropathies, Familial	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TEGSEDI

Trials by Country

Map
Table

Trials by Country for TEGSEDI
Location	Trials
United States	20
France	4
Taiwan	4
Brazil	3
Italy	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for TEGSEDI
Location	Trials
Pennsylvania	2
Oregon	2
New York	2
Minnesota	2
Massachusetts	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TEGSEDI

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for TEGSEDI
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for TEGSEDI
Clinical Trial Phase	Trials
Active, not recruiting	1
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TEGSEDI

Sponsor Name

Chart
Table

Sponsor Name for TEGSEDI
Sponsor	Trials
Ionis Pharmaceuticals, Inc.	2
GlaxoSmithKline	1
Akcea Therapeutics	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for TEGSEDI
Sponsor	Trials
Industry	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.